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Multiplicity of fibronectin-binding ax integrin receptors in colorectal cancer
MV Agrez', RC Bates2, D Mitchell', N Wilson3, N Ferguson3, P Anseline4 and D Sheppard5
'Discipline of Surgical Science, 2Cancer Research Unit, 3 Department of Pathology, 4 Department of Surgery, John Hunter Hospital,
Newcastle, Australia; 5Lung Biology Center, University of San Francisco, USA.
Summary Current data from in vitro and in vivo animal models indicate that fibronectin-binding integrin
receptors expressed by colon cancer cells may regulate tumour growth. While individual members of the #1
subfamily of integrins have now been clearly identified in colorectal cancer, little information exists with respect
to the cxv subfamily. In the present study we show that xv can associate with multiple and different ,B subunits
capable of binding fibronectin in this tumour type. This is likely to have functional implications for growth and
spread of colorectal cancer.
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The ability of tumour cells to invade surrounding tissues is a
fundamental characteristic of malignant neoplasms. Extra-
cellular matrices play a significant role in regulating the
behaviour and differentiation of neoplastic cells during this
process. These matrices include various collagens and non-
collagenous glycoproteins such as laminin and fibronectin,
which exert their effect through an array of cell membrane
receptors, the best characterised of which is a family of
transmembrane molecules termed integrins (Hynes, 1992).
The integrin receptors are heterodimeric complexes of an
alpha (a) and beta (13) subunit in non-covalent association.
Excluding the leucocyte integrins, which are designated by
the 12 nomenclature, and which mediate cell-cell interac-
tions, integrins can be divided into two major groups. The 1,
subfamily, also designated VLA (very late antigen), defines
one group in which the /, chain combines with nine a chain
members (cx, 9) (Palmer et al., 1993). Within this subfamily,
integrins that bind fibronectin are 541,, 04#1 and cX3#, (Hynes,
1992). The a4 subunit is restricted mostly to lymphoid and
myeloid cells and immunostaining of human colon cancers
has not revealed the presence of a4#, (Stallmach et al., 1992).
However, other members of the 1,I subfamily of integrins
(@2131, 031,, CO5,1 and aC6, are expressed in abundance in the
normal colon, although individual P, integrins may be lost
during tumour progression (Choy et al., 1990; Koretz et al.,
1991; Stallmach et al., 1992; Nigam et al., 1993; Lindmark et
al., 1993). A systematic study of integrin expression in normal
colon, adenomas and carcinomas within the same patients
has shown progressive loss of expression of 013, (which also
recognises laminin and collagen) and a5#1, (which recognises
fibronectin only) in the transition from adenomas to
carcinomas (Pignatelli et al., 1990; Stallmach et al., 1992).
In one report 75% of colorectal carcinomas were found to be
completely negative for expression of the major VLA
fibronectin receptor, CX5#I (Stallmach et al., 1992).
The other subfamily of integrins, designated cxv, is so
named because the cxv subunit is capable of associating with
multiple 13 subunits, including 1,, 3 PI, P6 and #38 in various
cell lines, but the primary functional role of this subfamily in
cancer progression is still unclear (Cheresh et al., 1989;
Bodary and McLean, 1990; Vogel et al., 1990; Orlando and
Cheresh, 1991; Wayner et al., 1991; Moyle et al., 1991; Busk
et al., 1992). Of these receptors, av1,, a003 and avB6 and
perhaps (Xv#5 are capable of binding fibronectin (Hynes, 1992;
Zhang et al., 1993; Charo et al., 1990; Cheng et al., 1991;
Busk et al., 1992; Weinacker et al., 1994). Some clues as to
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the function of the a, subfamily of receptors in tumorigenesis
have come from melanoma studies in which the presence of
the ax03 integrin (which binds multiple ligands, including
fibronectin) has been shown to correlate with enhanced
invasiveness of melanoma cells in vitro and increased
melanoma growth in vivo (Seftor et al., 1992). In contrast,
the 13 subunit has either not been identified at all in normal
and malignant epithelium (Stallmach et al., 1992) or found to
be weakly expressed in a minority of tissue specimens (Nigam
et al., 1993). On the other hand weak expression of a, has
been reported for the majority of normal mucosal specimens
and half of the tumours in one series of patients (Nigam et
al., 1993).
It has been suggested that expression of fibronectin
receptors and the assembly of fibronectin matrix is closely
associated with a tumorigenic phenotype (Ruoslahti, 1991).
For example, in hepatocellular and breast carcinomas a
correlation has been established between poorer differentia-
tion of tumours and up-regulation of expression of some
extracellular matrix molecules including fibronectin (Jaskie-
wicz et al., 1993). These matrix changes have been observed
at the interface between tumour and invaded tissues,
suggesting a role for these matrix molecules in invasive and
growth-stimulatory events. Indeed, we have previously
reported that fibronectin can stimulate growth of colon
cancer cells cultured within three-dimensional collagen
matrices (Agrez, 1989). These findings are consistent with
the recent proposal that the major fibronectin-binding
integrin of the f13 subfamily, ac,1,, functions as a negative
growth regulator when not bound to its ligand, whereas when
the receptor is occupied the negative signal is relieved and/or
a positive growth signal is generated (Juliano and Varner,
1993). Moreover, recent data from our laboratory have
shown that one member of the oe, subfamily that binds
fibronectin, a,,6, also enhances growth of colon cancer cells
in vitro and in vivo (Agrez et al., 1994). In the present study
we present our characterisation of fibronectin-binding oev
integrins on colon cancer cells, and consider the functional
implications of receptor redundancy in this tumour type.
Methods and materials
Cell lines
Three colon cancer cell lines, COLO 205, SW480 and WiDr,
were obtained from the American Type Culture Collection
(ATCC, Rockville, MD, USA). Another line, designated
020588, has previously been established in our laboratory
(Agrez et al., 1991) and another cancer cell line, LIM 1215,
was a generous gift from Dr R Whithead, Ludwig Institute of
Cancer Research, Melbourne, Australia. All lines were
adapted to monolayer growth in tissue culture flasks using
standard culture medium consisting of Dulbecco's modified
"A amLXV integrins in colorectal cancer
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eagle's medium (DMEM) (Flow Laboratories, VA, USA)
supplemented with glutamine, antibiotics (penicillin and
streptomycin) and 10% fetal calf serum.
Antibodies and peptides
Monoclonal antibodies (MAbs) to the ocv subunit (13C2) and
oe,#3 complex (23C6) (Davies et al., 1989) were a kind gift
from Dr Michael Horton of the Imperial Cancer Research
Fund, London, and anti-fl3 subunit (SZ21) was a kind gift
from Dr Michael Berndt of the Baker Institute, Melbourne,
Australia. Antibody to the flI subunit (QE.2E5) was a kind
gift from Dr Grahame Russ of the Queen Elizabeth Hospital,
Adelaide, Australia. Monoclonal antibodies against f5 (PIF6)
and f6 (E7P6) were prepared as previously described
(Weinacker et al., 1994). Antibody against o3 (P1B5) was
obtained from Telios (San Diego, CA, USA) and antibody
against L5 (SAM-1) was supplied by Immunotech, France.
The polyclonal anti-fl antibody 3847, was a kind gift from
Dr Ken Yamada (NIH). The polyclonal anti-human
vitronectin receptor (anti-VNR) antibody was purchased
from GIBCO BRL (Grand Island, NY, USA).
Immunostaining of resected colon specimens
Immunofluorescence Fresh tissue blocks were taken from
non-necrotic areas of colon cancers and mounted in OCT
compound (Miles), snap frozen in liquid nitrogen and cut in
a Microm cryostat (Zeiss, West Germany). Frozen sections 5
gM thick were placed on glass slides coated with 0.1% poly-L-
lysine (Sigma, St Louis, MO, USA) and fixed briefly (30 s) in
chilled acetone. Sections were washed with phosphate-
buffered saline (PBS) and incubated with optimally diluted
primary antibody in a humid chamber for 30 min. After
washing with PBS for 5 min, sections were then incubated in
the dark with FITC-conjugated anti-mouse IgG (Dako,
Denmark). Sections were mounted using glycerol/PBS 9:1
(v/v) pH 8.6 containing 2.5% DACO [1,4-diazobicyclo (2.2.2)
octane; Aldrich Chemical Co., Milwaukee, WI, USA] to
inhibit quenching of fluorescence. Negative controls using
irrelevant antibody were run with each batch of slides. The
slides were examined using a Nikon Optiphot microscope
with fluorescence and UFX camera attachments.
Immunoperoxidase Sections were cut and fixed as for
fluorescence staining. Before staining, sections were treated
with 3% hydrogen peroxide to quench endogenous perox-
idase activity, washed in PBS and incubated in non-immune
goat serum (Dako, Denmark) for 20 min. Without washing,
excess serum was removed and optimally diluted antibodies
applied for 30 min. All incubations were carried out in a
humid chamber at room temperature. After a brief wash in
PBS, sections were sequentially incubated for 30 min in
biotinylated anti-mouse IgG (1:200, Dako, Denmark) and
preformed streptavidin -biotin complex (Dako K377). The
presence of antigen was visualised by staining with DAB (5
mg 3,3 diaminobenzidine tetrahydrochloride; Sigma, in 10 ml
of 0.95 M Tris-HCl buffer pH 7.6 with 10 yil of 30%
hydrogen peroxide) for 5 min. Sections were counterstained
with Harris haematoxylin, dehydrated and mounted with
Ultramount (Fronine, Riverstone, Australia). Appropriate
positive and negative controls were run in parallel with each
batch of slides. The slides were examined on a Nikon
Optiphot microscope.
Cell staining andflow cytometric analysis Cells from each of
the five tumour cell lines were harvested from monolayer
cultures using 20 mM EDTA, washed once with DMEM, and
resuspended in normal goat serum at 4'C for 10 min to block
non-specific binding of the secondary antibody (goat anti-
mouse IgG). The cells were then incubated with the candidate
antibodies for 20 min at 4°C and washed twice with PBS. The
cell mixture was then stained with secondary antibody
conjugated to phycoerythrin (Boehringer Mannheim) for 20
A
B
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Figure 1 (a) Immunohistological staining of the a, integrin chain
in normal mucosa (left) and in a colon adenocarcinoma (right)
using the 13C2 monoclonal antibody (magnification x 200). (b)
Immunohistological staining of the f3 subunit in a colon
adenocarcinoma using the SZ21 monoclonal antibody (magnifi-
cation x 400). (c) Immunohistological staining of the f6 subunit
in normal mucosa (left) and in a colon adenocarcinoma (right)
using the E7P6 monoclonal antibody (magnification x 100).
min at 4°C, washed twice with PBS and resuspended in PBS
for analysis with FACScan (Becton Dickinson, Rutherford,
NJ, USA).
Immunoprecipitation Cells were labelled at the cell surface
by lactoperoxidase-catalysed iodination, essentially as pre-
viously described (Krissansen et al., 1990). The cells were
then washed three times to remove unbound label and
solubilised in octylglucoside lysis buffer (100 mmol 1-0-N-
octyl-fl-D-glucopyranoside, 1OyM Tris, 150pM sodium
chloride, 2 uM phenylmethylsulphonyl fluoride (PMSF), 20
4.
A
.11
.4
gM iodoacetamide and 50 jug ml-' soybean trypsin inhibitor)
for 1 h on ice. The lysates were centrifuged at 10 000 g for 10
min, then precleared with RAM (rabbit anti-mouse
immunoglobulin) coupled to Sepharose 4B beads for 2 h.
Immunoprecipitations were carried out using antibodies
directly coupled to Sepharose 4B and analysed by sodium
dodecyl sulphate - polyacrylamide gel electrophoresis (SDS-
PAGE) (7.5% gel) and autoradiography as described
previously (Bates et al., 1991).
Immunoblotting Cell lysates were immunoprecipitated essen-
tially as described above, however, protein-A coupled-
Sepharose 4B beads were used with the polyclonal anti-
VNR and anti-/,3 antibodies. Immunoprecipitates were
subjected to non-reducing 7.5% SDS-PAGE, then electro-
phoretically transferred to nitrocellulose membrane. The
membrane was probed with the anti-/,3 MAb QE.2E5, and
developed using an HRP-conjugated goat anti-mouse
secondary (Bio-Rad, Hercules, CA, USA), followed by
enhanced chemiluminescence (ECL) detection (DuPont
NEN, Boston, MA, USA).
Results
Immunostaining offresh tissue specimens
Initially, tissue sections were prepared from three primary
colorectal malignancies and tested for the distribution of Ov
and P3 using the MAbs 13C2 and SZ21 respectively.
Immunofluorescent preparations of all sections with anti-
body against oa revealed abundant expression of the a,
subunit in tumour cells as well as in normal mucosa
(Figure la). In contrast, the /3 subunit was detected only in
stromal cells within interstitial planes between tumour cell
COL0205
av~l
av integrins in colorectal cancer
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islands, and in none of the sections was P3 expressed on
tumour cells (Figure lb).
A further 12 primary tumours were stained with MAb
E7P6 against the /6 integrin subunit (fibronectin and tenascin
receptor). 6 was identified in 6 of these 12 specimens. In each
tumour, patchy expression was restricted to the epithelial
component and in some cases, expression of /6 was most
prominent within malignant cells located at the advancing
edges of tumour cell islands (Figure ic). There was no
correlation between the amount of /6 staining in tumour
specimens and either histological grade or clinico-pathologi-
cal stage of the cancers.
FACScan analyses
To determine whether established human colon cancer cell
lines also displayed a, but lacked surface expression of the /3
integrin, we examined a panel of 5 tumour cell lines by means
of FACScan analysis. The fluorescent profiles for two
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Figure 2 Fluorescence-activated cell analyses histograms show-
ing expression of integrin subunits in two human colon cancer cell
lines (COL0205 and SW480). av was detected with monoclonal
antibody 13C2; pI with QE2E5; avI3 complex with 23C6; /5 with
PIF6; and fl6with E7P6.
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Figure 3 Fluorescence-activated cell analyses histograms show-
ing expression of a5 and P6 subunits in five human colon cancer
cell lines (COL0205, SW480, WiDr, LIM1215 and 020588). oC5
was detected with monoclonal antibody SAM-1, and P6 with
E7P6.
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representative cell lines, COLO 205 and SW480 are shown in
Figure 2, and it is clear that these cells express av in
association with various /3 subunits on the cell surface. COLO
205 expressed high levels of av integrin, as well as the /5
subunit (primarily a vitronectin receptor) and /36 subunit, but
no /3. In contrast, SW480 cells displayed a, expression on the
cell surface in association with /3s but this line lacked
expression of /6. The SW480 cells also expressed the /3
subunit as the av/33 complex-however, this expression was
more than an order of magnitude lower than that of the /3s
subunit. All four remaining cell lines expressed /6 as shown in
Figure 3. The pattern of integrin expression shown for the
COLO 205 cells, a, in association with both /5 and /6
subunits in the absence of /3, was the same for the cell lines
LIM 1215 and 020588, while the remaining line WiDr
expressed both /35 and /6 as well as low levels of the /3
subunit (see Table I).
Although /3I was expressed on the surface of all five cell
lines (see Table I), expression of ac was restricted to three
lines, COLO 205, LIM 1215 and SW480 as shown in Figure
3. In contrast, all cell lines were strongly positive for a3 and
on none of the lines was there detectable expression of the a4
subunit (data not shown).
Immunoprecipitation analysis
To confirm the association of av with different /3 subunits and
to determine whether this subunit also associated with /31 on
Table I FACScan analyses of expression of various integrin
subunits on human colon cancer cell lines
SW480 COLO 205 020588 WiDr LIMJ215
0tv + + + + +
#I + + + + +
f3 + - - + _
f5 + + + + +
16 - + + + +
a
Mr
200
b
co oa 00 0
co ,- 0o 0 L- 00 r-
O I*
-i°n lenN ~ 0 N
cl) Cu 3: CI)
colon cancer cells, immunoprecipitations of lysates of cells
surface-labelled with "25I were performed with the monoclonal
antibody 13C2 against a,, subunits. The results confirmed the
presence of the a, integrin in association with multiple and
varied P subunits (Figure 4a) on all five cell lines tested. In
three cell lines, designated 020588, LIM 1215 and WiDr, but
not in SW480 and COLO 205 cells, a band of approximately
120 kDa co-precipitated with av (Figure 4a). To confirm the
physical association of a, with /3, in these three tumour cell
lines, cell lysates were immunoprecipitated with anti-oxv
antibody and the transferred proteins immunoblotted with
anti-#, antibody. A prominent band at approximately 120
kDa was identified on immunoblots (Figure 4b) that migrated
to the same position as /31 in control immunoblots of
LIM1215 and SW480 cells that had been immunoprecipi-
tated with anti-/3, antibody (Figure 4c). The lower band in
Figure 4c most likely represents the pre-/,3 chain previously
identified in human colonic carcinomas (von Lampe et al.,
1993; Fujita et al., 1995). In contrast, immunoprecipitation
and immunoblotting of lysates from SW480 and COLO 205
cells did not show /31 in association with av (Figure 4b).
Taken together with the FACScan results, it was apparent
that at least two cxv integrin receptors potentially capable of
binding fibronectin (av/3,, V/33, av#5 or ocvf/6) were present on
each of the colon cancer cell lines tested.
Discussion
Tumour growth, invasion and metastasis is likely to be
determined by the balance between available integrin
receptors present on tumour cells and the nature of the
surrounding matrix environment. For example, in the /3I
integrin subfamily, significant loss of tissue staining for two
fibronectin-binding integrins, a3 and CX5, has been reported in
colorectal cancers (Pignatelli et al., 1990; Stallmach et al.,
1992). The effect of a3 occupancy by fibronectin on tumour
cell growth is not known. It has been suggested that a3 has a
lower affinity for fibronectin than a5, and in contrast to the
diminished expression of a, by rodent fibroblasts consequent
C
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anti-av anti-av
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anti-ol
Figure 4 (a) Immunoprecipitation analysis of colon carcinoma cell lines. Cells were surface labelled with 1251, immunoprecipitated
with the anti-a, MAb 13C2, and analysed by SDS-PAGE and autoradiography. Precipitation of a, complexes are shown for all five
lines under non-reducing conditions. Varied expression and multiple 13 subunits are seen complexed with a,. (b) Immunoblot analysis
of ao,-defined complexes from colon carcinoma cell lines. The same five cell lines were immunoprecipitated with an anti-av complex
antibody, transferred to nitrocellulose and probed with the anti-fl, MAb QE.2E5. The identity of the approximately 120 kDa band
associating with av shown in (a) for lines 020588, LIM 1215 and WiDr is thus confirmed as ,BI. (c) l,1 immunoblot controls for av,,B-
expressing and -non-expressing cell lines (LIM1215 and SW480 respectively). The two lines were immunoprecipitated with
polyclonal fl3 antibody and probed with QE.2E5, as in b.
a, integrins in colorectal cancer
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upon activation of ras oncogenes, expression of a3fl1 remains
unaltered in the transformed cells (Ruoslahti and Giancotti,
1989; Plantefaber and Hynes, 1989). On the other hand,
expression of a5flb the 'classical' fibronectin receptor, is
required for deposition of a fibronectin matrix, and ectopic
expression of a5A3 by transfection into human colon cancer
cells has been associated with a marked reduction in
tumorigenicity in nude mice (Plantefaber and Hynes, 1989;
Varner et al., 1992). In contrast, in melanoma cell lines the
arginine-glycine-aspartate - containing 120 kDa fibronectin
fragment has been shown to stimulate mitogenesis only in
those clones expressing a^5l1 (Mortarini et al., 1992).
Interestingly, three of the five colon cancer cell lines tested
in the present study expressed aX suggesting that loss of this
receptor in colon cancer may not be a general phenomenon
as implied from immunostaining data.
The av integrin subfamily is also thought to play an
important role in tumour cell growth and invasion for some
cell types. For example, loss of af33 expression in melanoma
cell variants leads to reduced in vivo tumour growth (Felding-
Habermann et al., 1992). Although we observed abundant a,
on malignant colonic epithelium, this did not appear to be
associated with P3 (which binds multiple ligands including
vitronectin and fibronectin). Instead, strong staining for the P3
integrin was seen in cells resembling fibroblasts and host
macrophages immediately subjacent to basement membranes
surrounding tumour cell islands, consistent with the essentially
stromal distribution of af33 as reported by others (Nigam et
al., 1993). However, FACScan analysis did reveal the presence
of f, albeit in low amounts, expressed on the surface of two of
the five cell lines (Figure 2 and Table I). More importantly, all
but one of the cell lines expressed the fibronectin-binding 16
subunit, which has been shown to enhance colon cancer cell
growth in vitro and in vivo (Agrez et al., 1994).
It is now recognised that the a, subunit can also associate
with PI forming an integrin that is thought to have a lower
affinity for fibronectin that a5fl1 (Zhang et al., 1993). The #
subunit at approximately 120 kDa found on immunoprecipi-
tations with anti-a, antibody in three of the cell lines studied,
was shown to be #I, and the acfli combination appears to be
quite widely distributed (Bates et al., 1991; Bodary and
McLean, 1990; Bossy and Reichardt, 1990). The role of this
receptor in colon cancer progression is not known, although in
Chinese hamster ovary cells induced to express avfl1, this
receptor binds fibronectin but does not facilitate cell migration
on this substrate (Zhang et al., 1993). It is also possible that
receptor co-operativity is required between avfli and ax5/ with
respect to fibronectin-mediated growth events. For example,
the only cell line previously shown to be stimulated to
proliferate within three-dimensional collagen gels in response
to exogenous fibronectin is LIM 1215 (Agrez, 1989), and this
is the only line in the present study characterised by expression
of both a5,fi and ax,#3 receptors.
In summary, we have shown that in the same colon cancer
cell line the av subunit can associate with more than one /
subunit, and that the /3 subunits associated with av differ
between different cell lines. Moreover, it is now clear that
Oc06 is a major fibronectin-binding receptor in colorectal
cancer. The present study suggests that discrepancy may exist
in expression of fibronectin-binding integrins between tumour
tissues and established cell lines. Such differences may reflect
the masking of different epitopes on integrin receptors by
tissue fixation techniques on the one hand, or alternatively,
selective pressures associated with the establishment of
continuous cell lines. Whatever the reason, the effects of
multiple receptors for a given ligand such as fibronectin are
likely to be complex, and determined by such factors as
availability of cell-binding sites on fibronectin, the relative
affinities of fibronectin receptors for their ligand, and
differing effects of fragments of fibronectin compared with
the intact ligand (Damsky and Werb, 1992).
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